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 CURRENTOPINION Small, dense LDL: an update
Philipp A. Gerbera, Dragana Nikolicb, and Manfredi Rizzob
Purpose of review
In this review, we summarize the latest findings on small, dense LDL (sdLDL) atherogenic particles, including
their associations with other biomarkers.
Recent findings
Increased sdLDL levels have been reported not only in different metabolic disorders such as diabetes,
obesity and metabolic syndrome, but also in patients with rheumatoid and psoriatic arthritis as well as
hypothyroidism. A wide range of lipid-lowering, as well as other drug classes, including novel antidiabetic
agents and nutraceuticals, exert favourable effects on these atherogenic particles. The ‘gold standard’
methodology for the assessment of sdLDL has not been established yet. However, the association between
sdLDL and several biomarkers could facilitate their assessment.
Summary
Estimation of sdLDL in daily clinical practice may help with the identification of patients at high cardiovascular
risk and further contribute in directing specific interventions to prevent and/or decrease such risk.
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INTRODUCTION
Small, dense LDL (sdLDL) particles are associated
with an increased cardiovascular risk [1] that further
extends the individual risk assessment beyond the
traditional risk markers in patients with dysglycae-
mia [2], obesity [3] or different ethnicities [4]. LDL
particles transport lipids as well as carry proteins
involved in inflammation and thrombosis, and the
sdLDL proteome in diabetic individuals differs sig-
nificantly from that of larger LDL [5]. Further, a lipid
profile with a prevalence of sdLDL is associated with
cardiac autonomic neuropathy in diabetic women
[6]. Some studies also report elevated sdLDL-choles-
terol (sdLDL-C) concentrations in chronic kidney
disease patient [7]. Thus, sdLDL, together with other
clinical parameters, may have a predictive role in
screening as well as provide a novel approach in
lipid management and further cardiovascular
benefit [8], potentially becoming a new therapeutic
target.
In this review, we summarize the latest findings
on these atherogenic particles, including their
associations with other biomarkers.
PREDICTIVE ROLE OF SMALL, DENSE LDL
The association between sdLDL and different cardio-
vascular risk markers has not been thoroughly
investigated. One prospective longitudinal cohort
study in 39 patients with (pre)diabetes with a follow-
up of 2 years showed that the proportion of sdLDL
particles and changes in this proportion are predic-
tive of changes in carotid intima–media thickness
(cIMT) and insulin resistance. There was also an
association with other determinants of an adverse
metabolic status (e.g. serum resistin levels increased
with the increasing in sdLDL, whereas serum adi-
ponectin increased only in patients with unaltered
sdLDL) [2]. On the other hand, the change in flow-
mediated dilation was predicted by LDL-C levels [2].
Thus, sdLDL-C may be a useful risk marker when
assessing changes in cIMT, including Japanese and
Chinese populations [9,10], as well as in the risk
assessment for atherosclerotic disease in patients
with psoriatic arthritis [11]. Consecutive studies
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regarding peripheral arterial disease extended the
predictive value of sdLDL, which was shown to be
able to predict the early outcome of angioplasty [12].
The ratio (LDL3-to-LDL6)/LDL1 is proposed as a
marker for evaluating lipid metabolic status in
patients with the metabolic syndrome (MetS) [13].
Among different MetS components, only increased
triglyceride level was a differentiating factor for
sdLDL-C concentration and sdLDL-C/LDL-C ratio
in both sexes, with or without MetS [14]. However,
this trend was not seen, unexpectedly, in youths
with recent-onset type 2 diabetes (T2DM) (TODAY
study) [15].
Compared with simple steatosis, nonalcoholic
steatohepatitis (NASH) patients have increased
levels of sdLDL that may, at least partly, explain
the increased risk for atherosclerosis and cardiovas-
cular diseases in these patients [16
&
]. In this context,
LDL migration index, an indicator of sdLDL, was
higher in patients with NASH compared with those
with nonalcoholic fatty liver diseases [17].
sdLDL is an important correlate of atherosclero-
sis in postmenopausal women, and it has been
shown that a decrease in antioxidant capacity of
paraoxonase1 (PON1), a HDL-associated enzyme
that prevents oxidative modifications in LDL and
HDL is associated with an increase in sdLDL-C in
these women [18]. On the other hand, although it is
clear that lower LDL peak diameter and a predom-
inance of sdLDL are associated with T2DM, it is
unclear whether they are a risk factor for gestational
diabetes mellitus (GDM) [19]. Apolipoprotein E4
genotype has been shown to be associated with
increased total cholesterol (TC) and LDL-C during
pregnancy, with a reversible remodelling of LDL to
smaller particles, which may further indicate a pre-
disposition to atherosclerosis [20]. The atherogenic
lipid profile in both prepregnancy and pregnancy
period may help identify women at risk and prevent
GDM [21,22].
EFFECTS OF DIFFERENT DRUG CLASSES
ON SMALL, DENSE LDL
High-dose statin therapy significantly reduced
sdLDL and malondialdehyde-modified LDL-C com-
ponents of atherosclerotic lipoproteins, as oxidized-
LDL (oxLDL) and remnant-like particle-C, without
adverse events compared with low-dose statin
therapy (The Standard versus high-dose therApy
with Rosuvastatin for lipiD lowering trial) [23
&
].
Patient-tailored atorvastatin therapy ameliorated
atherogenic LDL particle size and inflammation,
in addition to achieving the target LDL-C level
without an undesirable effect on glycaemic control
in patients with T2DM [24]. In addition, switching
from atorvastatin (10mg) to rosuvastatin (5mg)
may be a useful therapeutic option to reduce
sdLDL-C levels in Japanese people with diabetes
with hypercholesterolaemia [25]. Recently, it has
been suggested that targeting distinct LDL subfrac-
tions may reduce the residual risk seen in patients
taking statins [26].
It has been reported that the effects of the cho-
lesterol ester transfer protein (CETP) variation on
LDL subfraction could change in conditions such as
coronary heart disease (CHD) and statin therapy.
This was based on the findings [27] that the CETP
rs708272 single nucleotide polymorphisms together
with statin therapy may show a favourable effect on
antiatherogenic LDL-1 and large-LDL subfractions
in CHD patients with an atherogenic effect on large
LDL subfraction in healthy patients.
The effectiveness of ezetimibe on LDL subfrac-
tions is controversial [28], although some studies
reported that ezetimibe alone and in combination
with statin reduced atherogenic sdLDL in patients
with T2DM and glucose intolerance as well as in
patients with insulin resistance [29]. As an add-on
therapy to statins, ezetimibe reduced sdLDL-C-
related residual risk of cardiovascular disease with-
out affecting absorption of supplemental eicosapen-
taenoic acid (EPA) in patients with coronary artery
disease [30]. Ezetimibe/simvastatin combination
represents a well tolerated and efficacious choice
for dyslipidaemia treatment in high-risk patients
based on positive results of the IMProved Reduction
of Outcomes: Vytorin Efficacy International Trial
[31].
Cilostazol, a selective inhibitor of phosphodi-
esterase type 3, improves the proatherogenic lipid
profile in patients with peripheral arterial disease or
T2DM [32]. However, whether such treatment exerts
KEY POINTS
 sdLDL is a determinant of atherosclerosis associated
with different traditional risk markers in a wide range
of metabolic disorders.
 The evidence supports favourable effects of different
lipid-lowering, as well as other drug classes on these
atherogenic particles.
 Estimation of sdLDL, together with other clinical
parameters, may have a predictive role in the
identification of patients with cardiovascular risk. sdLDL
might also provide a novel approach in lipid
management with specific interventions for
cardiovascular prevention and by decreasing residual
cardiovascular risk after use of standard and/or novel
lipid-lowering drugs.
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clinically relevant effects in high-risk patients
remains to be established by future studies.
The association of sdLDL with a novel regulator
of LDLmetabolism, proprotein convertase subtilisin
kexin type 9 (PCSK9), is still unclear. It has been
demonstrated that plasma sdLDL-C are positively
related to PCSK9 in patients undergoing coronary
angiography, suggesting an interaction between
sdLDL-C and PCSK9 in CHD [33
&
].
Significantly, baricitinib, a drug for the treat-
ment of rheumatoid arthritis, led to a mean increase
in LDL-C increasing large and reducing sdLDL
particles [34].
After glimepiride treatment in addition to
dipeptidyl peptidase-4 (DPP-4) inhibitors, LDL-C
and sdLDL levels decreased, whereas after mitigli-
nide/voglibose fixed-dose combination LDL-C
levels did not change, but sdLDL and sdDL/LDL-C
decreased and LDL-C/apoB increased significantly.
Such differences after treatment with these two
agents in addition to DPP-4 inhibitors have been
suggested to be related to fluctuations in blood
glucose levels [35].
Very recently, it has been reported that a
sodium/glucose cotransporter 2 inhibitor, dapagli-
flozin, decreases atherogenic sdLDL-C and increases
HDL2-C [36
&
]. LDL-C levels were elevated by dapa-
gliflozin; however, this was due to increased con-
centrations of the less atherogenic lb LDL-C. Such
findings were not seen after treatment with DPP-4
inhibitor, sitagliptin [36
&
].
EFFECTS OF NUTRACEUTICALS ON
SMALL, DENSE LDL
Bedard et al. [37] highlighted the importance of
considering sex in cardiovascular benefits of the
consumption of Mediterranean diet (MedDiet) on
LDL Particle Size Distribution and Oxidation,
because only men experienced a favourable redis-
tribution of LDL subclasses, whereas an opposite
trend was observed in women. Similarly, only
men experienced a reduction in cholesterol concen-
trations among sdLDL, whereas oxLDLwere reduced
with no sex difference [37].
Lower sdLDL-C concentrations have been
reported after 12-week supplementation with flax-
seed oil, a rich source of alpha-linolenic acid [38].
Four-week supplementation with curcuminoids,
polyphenolic compounds with diverse potential
cardioprotective functions, was not associated with
changes in sdLDL concentrations [39], whereas a
beneficial effect of chitosan on LDL subclasses, with
a significant increase in LDL-2 particles and a
decrease (although not significantly) in atherogenic
sdLDL, was found [40].
Avocados are known as a nutrient-dense
source of monounsaturated fatty acids (FAs) that
can be used to replace saturated FAs in a diet to
lower LDL-C. Inclusion of one avocado per day
as part of a moderate-fat, cholesterol-lowering
diet, has beneficial effects on cardiometabolic
risk factors that extend beyond their heart-healthy
FA profile, especially for sdLDL [41]. In addition,
the combination of a standard diet with Armolipid
Plus; MEDA-Rottapharm S.p.A. (Monza, Italy)
treatment (nutraceutical combination of red
yeast rice extract, berberine, policosanols, folic
acid, coenzyme Q10 and astaxanthin) in patients
with familial combined hyperlipidaemia was
able to reduce the LDL score and increase LDL
particle diameter after only 8 weeks of treatment
[42
&
].
Dietary supplementation with marine n-3 poly-
unsaturated FAs may have a beneficial effect on
sdLDL particles, but had no effect on LDL density
or sdLDL levels in patients with end-stage renal
disease [43
&
]. On the other hand, the lipid effects
of two different prescription omega-3 FA therapies
[omega-3-acid ethyl esters (EPA and docosahexae-
noic acid 4 g/day and then switched to icosapent
ethyl (high-purity EPA ethyl ester) 4 g/day] are
described as well tolerated in a 55-year-old statin-
treated and niacin-treated woman with severe dys-
lipidaemia and high cardiovascular risk, with
improvements maintained over 2 years [44].
Approximately, 28 months after switching to icosa-
pent ethyl, LDL-C, triglycerides, non-HDL-C and TC
decreased, whereas HDL-C increased. Importantly,
total and sdLDL particle concentrations decreased
by 60 and 59%, respectively [44].
Recently, the effects of considerable weight loss
and intensive exercise training on lipid atheroge-
nicity and low-grade inflammation were estimated
in a high-risk population with CHD. A low-energy
diet (LED) and 12 weeks’ aerobic interval training
decreased total and LDL lipoprotein. LED was
superior in decreasing atherogenicity (shift in
density profile and increased particle size), whereas
the effect on low-grade inflammation was limited
[45
&
]. Other studies could show that exercise train-
ing increases the proportion of large LDL particles
even in the context of an unfavourable diet with
fructose [46], which is known to reduce LDL particle
size in nonexercising patients [47].
COULD OTHER BIOMARKERS HELP
ESTIMATE THE LEVELS OF SMALL, DENSE
LDL?
A potential new link between lipid metabolism
dysregulation, innate immunity and atherosclerosis
Lipids and emerging risk factors
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has been suggested as atherogenic sdLDL is associ-
ated with an increase of nonclassical monocytes
and a decrease of monocytes [48]. In addition,
plasma resistin and peripheral blood mononuclear
cells (PBMCs) resistin mRNA were significantly
higher in CHD patients with a proportion of
sdLDL particles at least 50%, compared with the
group with proportion of sdLDL particles less than
50%. Such findings indicate that increased gene
expression of resistin in PBMCs and higher resistin
levels in plasma are related to proatherogenic
LDL particle phenotype [49]. Yet, multiple linear
regression analysis revealed LDL particle diameter
as the only independent predictor of resistin
mRNA.
Yu et al. [50] investigated the serum levels of
beta2-glycoprotein I-LDL (b2-GPI-LDL) and oxLDL
in patients with T2DM and further evaluated the
associations between these two parameters in vivo
and with the presence of diabetic microvascular
complications. The authors concluded that elevated
serum b2-GPI-LDL levels may be a serological hall-
mark of enhanced LDL oxidation in vivo and closely
associated with the presence of diabetic microvas-
cular complications [50]. Further, lipoprotein-
associated phospholipase A(2) may be a novel bio-
marker for the presence of rupture-prone athero-
sclerotic lesions in elderly patients, whereas its
level in diabetic patientsmay accompany the higher
sdLDL particles levels [51].
Obstructive sleep apnea (OSA) is associated with
dyslipidaemia and increased cardiovascular risk, and
the effects of apoE genotype on both LDL and HDL
particle size and lipid subclasses were assessed
recently in 181 patients with OSA [52
&
]. Both the
apoE genotype and MetS are independently related
to smaller LDL size in patients with OSA. Of interest,
LDL size was independently predicted not only by
apoE genotype, but also by male sex, and the pres-
ence of MetS.
The mean platelet volume (MPV) and red cell
distribution width (RDW) have attracted interest
because of their association with an increased car-
diovascular risk. Therefore, Kucera et al. [53] aimed
to determine if an association exists among MPV,
RDW and lipoprotein subfractions, and to show the
impact of statin therapy on these new possible
biomarkers of atherosclerotic risk. Forty patients
with hypercholesterolaemia, without previous
hypolipidaemic treatment, were enrolled and
treated with atorvastatin (40mg/day for 12 weeks).
Values ofMPV and RDW seem to reflect a proathero-
genic lipoprotein profile represented by the pres-
ence of sdLDL-C [53].
It has been shown that in overweight T2DM
patients, triacylglycerol/HDL ratio, a surrogate
marker of LDL particle size (small, dense), could
be used as a reliable marker for insulin resistance
[as measured by HomeOstasis Model Assessment
for estimating insulin resistance (HOMA-IR)] with
thyroid comorbidity (as measured using free thyro-
xine [T4]), while small dense LDL particles could
represent a link between insulin resistance and
thyroid disease [54].
CONCLUSION
The literature indicates that sdLDLs play a role in the
atherosclerotic process, may have a predictive role
in different cardiometabolic states and interact with
several traditional cardiovascular markers. Clinical
estimation of these atherogenic particles may
represent a fundamental marker in prompt assess-
ment of a high cardiovascular risk, but also might
help in designing effective treatment options.
Future studies will establish if a decrease in sdLDL
can improve cardiovascular and/or residual risk
after use of standard and/or novel lipid-modifying
therapy, including natural supplements.
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